To receive daily emails from Breaking Christian News to your inbox CLICK HERE

"Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today." -Dr. Gerald Weissmann

A new ray of hope has broken through the clouded outcomes associated with Alzheimer's disease. A new research report published in January 2013 print issue of the FASEB Journal (Federation of the American Societies for Experimental Biology) by scientists from the National Institutes of Health shows that when a molecule called TFP5 is injected into mice with disease that is the equivalent of human Alzheimer's, symptoms are reversed and memory is restored—without obvious toxic side effects.

"We hope that clinical trial studies in AD patients should yield an extended and a better quality of life as observed in mice upon TFP5 treatment," said Harish C. Pant, Ph.D., a senior researcher involved in the work from the Laboratory of Neurochemistry at the National Institute of Neurological Disorders at Stroke at the National Institutes of Health in Bethesda, MD. "Therefore, we suggest that TFP5 should be an effective therapeutic compound." (Photo by: Cécile Graat)

To make this discovery, Pant and colleagues used mice with a disease considered the equivalent of Alzheimer's. One set of these mice were injected with the small molecule TFP5, while the other was injected with saline as placebo. The mice, after a series of intraperitoneal injections of TFP5, displayed a substantial reduction in the various disease symptoms along with restoration of memory loss. In addition, the mice receiving TFP5 injections experienced no weight loss, neurological stress (anxiety) or signs of toxicity. The disease in the placebo mice, however, progressed normally as expected. TFP5 was derived from the regulator of a key brain enzyme, called Cdk5. The over activation of Cdk5 is implicated in the formation of plaques and tangles, the major hallmark of Alzheimer's disease.

"The next step is to find out if this molecule can have the same effects in people, and if not, to find out which molecule will," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today."

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

'Welcomed Win': Court Orders Hawaii to Allow Good News Clubs at Every Public School

FBI Warns Americans: Stop Sending Texts Between Android and Apple Devices; Here's What To Do Instead

Co-Writer of 'Y.M.C.A.' Glad Trump Used His Song at Rallies, Says It's NOT a Gay Anthem

Trump Voices the Moral Clarity on Hostages the World Needed

7 Takeaways from the Final Hearing of Task Force Investigating Trump Assassination Attempt

Black Church Coalition Demands MSNBC Investigate Kamala Harris Campaign's Payments to Al Sharpton Prior to Interview

President Trump Doubles-Down on His Support for Pete Hegseth for Defense Secretary

Daniel Penny Trial Judge Agrees to Drop Top Manslaughter Count after Jury Deadlocks Twice

Facing Potential Lawsuit, NJ Town Council Pres. Issues Obtuse 'Apology' after Ousting Man for Holding US Flag

Hezbollah Already Rebuilding Weapon Supply as Congress Honors Slain US-Israeli Soldier

America Last?: As People in North Carolina Are Still Living in Tents in the Cold, Biden Pledges More Money for Africa

Speaker Mike Johnson Nixes Biden's $24 Billion Aid Request for Ukraine [Video]

Trump Tackles Government Waste, Digital Currency, Space With Slew of Nominees

LPGA Tour Updates Gender-Eligibility Policy, Bars 'Players Assigned Male at Birth'

Justice Ketanji Jackson Makes a Fool of Herself during Oral Arguments in Trans Supreme Court Case

Supreme Court Tips Its Hand on Transgender Procedures for Minors

[Watch] Officers' 'Bravery in the Face of Danger' as They Saved Kids from a Burning Home: 'Hard to Believe Anyone Could Survive That'

Revealed: Biden Considered Pardoning Hunter in June but Directed Aides to Lie That He Wouldn't

Reports: Trump Mulls Replacing Pete Hegseth With Governor Ron DeSantis for Defense Secretary

Florida Sheriff Chad Chronister Withdraws as Trump's Nominee to Lead DEA

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor